Key Findings
• The main driver of growth in the schizophrenia market will be the uptake of novel pipeline products, such as Minerva Neuroscience’s MIN-101, Intra-Cellular Therapies’ ITI-007, and Alkermes’ ALKS-3831. The pipeline products are forecast to account for 36.2% of the schizophrenia market by 2025
So until the market for schizophrenia drugs becomes cure driven rather than profit driven we will be stuck with the same shyte that we have today.
Imagine where we would be today if there weren’t dozens of generic medications on the market driving prices down.
At least Intracellular were daring enough to come out with their new drug, after that innovation will probably be largely dormant because drug companies don’t have the balls to come out with something which might fail and cost them money. People are losing their jobs when these drugs fail.
It’s unfortunate that our medical field is completely driven by profit. In one hand you have all this money going into cutting edge research and then on the other you have these villainous drug companies that are out to turn a profit by making the cheapest possible solution to the problem.
I wish there was more incentive to produce a better medicine other than just a bunch of scientists that empathize with us schizophrenics for having to take these meds. Such is the case for all illnesses when you think about it, but at least other communities can speak for themselves. Nobody really cares about the mentally ill.